Eintrag weiter verarbeiten
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 27, 2009, 16, S. 2705-2711 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Kummar, Shivaani Kinders, Robert Gutierrez, Martin E. Rubinstein, Larry Parchment, Ralph E. Phillips, Lawrence R. Ji, Jiuping Monks, Anne Low, Jennifer A. Chen, Alice Murgo, Anthony J. Collins, Jerry Steinberg, Seth M. Eliopoulos, Helen Giranda, Vincent L. Gordon, Gary Helman, Lee Wiltrout, Robert Tomaszewski, Joseph E. Doroshow, James H. Kummar, Shivaani Kinders, Robert Gutierrez, Martin E. Rubinstein, Larry Parchment, Ralph E. Phillips, Lawrence R. Ji, Jiuping Monks, Anne Low, Jennifer A. Chen, Alice Murgo, Anthony J. Collins, Jerry Steinberg, Seth M. Eliopoulos, Helen Giranda, Vincent L. Gordon, Gary Helman, Lee Wiltrout, Robert Tomaszewski, Joseph E. Doroshow, James H. |
|---|---|
| author |
Kummar, Shivaani Kinders, Robert Gutierrez, Martin E. Rubinstein, Larry Parchment, Ralph E. Phillips, Lawrence R. Ji, Jiuping Monks, Anne Low, Jennifer A. Chen, Alice Murgo, Anthony J. Collins, Jerry Steinberg, Seth M. Eliopoulos, Helen Giranda, Vincent L. Gordon, Gary Helman, Lee Wiltrout, Robert Tomaszewski, Joseph E. Doroshow, James H. |
| spellingShingle |
Kummar, Shivaani Kinders, Robert Gutierrez, Martin E. Rubinstein, Larry Parchment, Ralph E. Phillips, Lawrence R. Ji, Jiuping Monks, Anne Low, Jennifer A. Chen, Alice Murgo, Anthony J. Collins, Jerry Steinberg, Seth M. Eliopoulos, Helen Giranda, Vincent L. Gordon, Gary Helman, Lee Wiltrout, Robert Tomaszewski, Joseph E. Doroshow, James H. Journal of Clinical Oncology Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Cancer Research Oncology |
| author_sort |
kummar, shivaani |
| spelling |
Kummar, Shivaani Kinders, Robert Gutierrez, Martin E. Rubinstein, Larry Parchment, Ralph E. Phillips, Lawrence R. Ji, Jiuping Monks, Anne Low, Jennifer A. Chen, Alice Murgo, Anthony J. Collins, Jerry Steinberg, Seth M. Eliopoulos, Helen Giranda, Vincent L. Gordon, Gary Helman, Lee Wiltrout, Robert Tomaszewski, Joseph E. Doroshow, James H. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.19.7681 <jats:sec><jats:title>Purpose</jats:title><jats:p> We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology. </jats:p></jats:sec> Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2008.19.7681 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xOS43Njgx |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xOS43Njgx |
| institution |
DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
| imprint |
American Society of Clinical Oncology (ASCO), 2009 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2009 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
kummar2009phase0clinicaltrialofthepolyadpribosepolymeraseinhibitorabt888inpatientswithadvancedmalignancies |
| publishDateSort |
2009 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_unstemmed |
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_full |
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_fullStr |
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_full_unstemmed |
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_short |
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_sort |
phase 0 clinical trial of the poly (adp-ribose) polymerase inhibitor abt-888 in patients with advanced malignancies |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2008.19.7681 |
| publishDate |
2009 |
| physical |
2705-2711 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology. </jats:p></jats:sec> |
| container_issue |
16 |
| container_start_page |
2705 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
27 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344924009529346 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:15:18.991Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Phase+0+Clinical+Trial+of+the+Poly+%28ADP-Ribose%29+Polymerase+Inhibitor+ABT-888+in+Patients+With+Advanced+Malignancies&rft.date=2009-06-01&genre=article&issn=1527-7755&volume=27&issue=16&spage=2705&epage=2711&pages=2705-2711&jtitle=Journal+of+Clinical+Oncology&atitle=Phase+0+Clinical+Trial+of+the+Poly+%28ADP-Ribose%29+Polymerase+Inhibitor+ABT-888+in+Patients+With+Advanced+Malignancies&aulast=Doroshow&aufirst=James+H.&rft_id=info%3Adoi%2F10.1200%2Fjco.2008.19.7681&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344924009529346 |
| author | Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H. |
| author_facet | Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H., Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H. |
| author_sort | kummar, shivaani |
| container_issue | 16 |
| container_start_page | 2705 |
| container_title | Journal of Clinical Oncology |
| container_volume | 27 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2008.19.7681 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4xOS43Njgx |
| imprint | American Society of Clinical Oncology (ASCO), 2009 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2009 |
| institution | DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T17:15:18.991Z |
| match_str | kummar2009phase0clinicaltrialofthepolyadpribosepolymeraseinhibitorabt888inpatientswithadvancedmalignancies |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 2705-2711 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Kummar, Shivaani Kinders, Robert Gutierrez, Martin E. Rubinstein, Larry Parchment, Ralph E. Phillips, Lawrence R. Ji, Jiuping Monks, Anne Low, Jennifer A. Chen, Alice Murgo, Anthony J. Collins, Jerry Steinberg, Seth M. Eliopoulos, Helen Giranda, Vincent L. Gordon, Gary Helman, Lee Wiltrout, Robert Tomaszewski, Joseph E. Doroshow, James H. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.19.7681 <jats:sec><jats:title>Purpose</jats:title><jats:p> We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology. </jats:p></jats:sec> Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Journal of Clinical Oncology |
| spellingShingle | Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H., Journal of Clinical Oncology, Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies, Cancer Research, Oncology |
| title | Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_full | Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_fullStr | Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_full_unstemmed | Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_short | Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| title_sort | phase 0 clinical trial of the poly (adp-ribose) polymerase inhibitor abt-888 in patients with advanced malignancies |
| title_unstemmed | Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2008.19.7681 |